Current treatment practices for anemia in patients with chronic kidney disease and future opportunities with hypoxia-inducible factor prolyl hydroxylase inhibitors: a narrative review-Reference-Cited by-同舟云学术

Current treatment practices for anemia in patients with chronic kidney disease and future opportunities with hypoxia-inducible factor prolyl hydroxylase inhibitors: a narrative review

Published:2020-08-08 Issue:2 Volume:53 Page:283-290
ISSN:0301-1623
Container-title:International Urology and Nephrology
language:en
Short-container-title:Int Urol Nephrol

Author:

Kile Mercedes,Sudchada Patcharaporn^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Urology,Nephrology

Link

https://link.springer.com/content/pdf/10.1007/s11255-020-02584-x.pdf

Reference30 articles.

1. The Kidney Disease: Improving Global Outcomes (KDIGO) (2012) KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney Int Suppl 2:271–335

2. National Clinical Guideline Centre (2015) Anaemia management in chronic kidney disease: update 2015 NICE guideline 8. National Institute for Health and Care Excellence (NICE). https://www.nice.org.uk/guidance/ng8. Accessed 26 Sept 2019

3. Locatelli F, Fishbane S, Block GA, Macdougall IC (2017) Targeting hypoxia-inducible factors for the treatment of anemia in chronic kidney disease patients. Am J Nephrol 45:187–199

4. Collister D, Rigatto C, Tangri N (2017) Anemia management in chronic kidney disease and dialysis: a narrative review. Curr Opin Nephrol Hypertens 26:214–218

5. Mikhail A, Brown C, Williams JA et al (2017) Renal association clinical practice guideline on anaemia of chronic kidney disease. BMC Nephrol 18:345

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Desidustat in anaemia in patients with chronic kidney disease: a profile of its use;Drugs & Therapy Perspectives;2023-07-13

2. Impact of erythropoietin on anemia in end-stage renal disease patients on hemodialysis;Medical Journal of Babylon;2023-07

3. A network meta-analysis of the efficacy of hypoxia-inducible factor prolyl-hydroxylase inhibitors in dialysis chronic kidney disease;Aging;2023-03-27

4. Disturbance of Hypoxia Response and Its Implications in Kidney Diseases;Antioxidants & Redox Signaling;2022-11-01

5. Contribution of HIF-P4H isoenzyme inhibition to metabolism indicates major beneficial effects being conveyed by HIF-P4H-2 antagonism;Journal of Biological Chemistry;2022-08